Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer

Table 1 Pretreatment characteristics

	sFOLFIRINOX	mFOLFIRINOX	P value
	(n = 88)	(n = 42)
Sex, n (%)			0.0041
Male	61 (69.3)	18 (42.9)
Female	27 (30.7)	24 (57.1)
Age, yr			0.0181
Median (range)	57 (31-79)	63.5 (41-77)
ECOG-PS, n (%)			0.426
0	68 (77.3)	35 (83.3)
1	20 (22.7)	7 (16.7)
Laboratory test results, median (range)
Absolute neutrophil count, /μL	4200 (1610-11170)	4525 (2080-18930)	0.317
Hemoglobin, g/dL	12.3 (7.1-17.1)	12.1 (8.5-14.9)	0.36
Platelet count, × 103/μL	218 (76-439)	245 (107-764)	0.247
Total bilirubin, mg/dL	0.7 (0.2-4.8)	0.5 (0.2-2.7)	0.144
Albumin, g/dL	3.9 (2.8-5.0)	3.9 (2.4-4.8)	0.797
Creatinine, mg/dL	0.67 (0.37-1.02)	0.70 (0.37-1.04)	0.516
Level of CA 19-9
U/mL, median (range)	172.2 (0.6-20000.0)	455.5 (0.7-20000.0)	0.709
Normal, n (%)	17 (19.3)	11 (21.5)	0.274
Elevated, < 59 × ULN, n (%)	53 (60.2)	19 (45.2)
Elevated, ≥ 59 × ULN, n (%)	18 (20.5)	12 (28.6)
Biliary drainage, n (%)			0.435
Presence	29 (33.0)	11 (26.2)
Tumor location in pancreas, n (%)			0.657
Head	40 (45.5)	16 (38.1)
Body and tail	44 (50.0)	23 (54.8)
Recurrent	4 (4.5)	3 (7.1)
Tumor size, cm			0.313
Median (range)	3.6 (1.3-7.7)	4.0 (1.3-8.0)
Disease extent, n (%)			0.243
Borderline resectable	17 (19.3)	6 (14.3)
Locally advanced	26 (29.5)	8 (19.0)
Metastatic	45 (51.1)	28 (66.7)
Stage, n (%)			0.248
II	24 (27.3)	8 (19.0)
III	19 (21.6)	6 (14.3)
IV	45 (51.1)	28 (66.7)
Prior treatment, n (%)
Naïve	75 (85.2)	33 (85.7)	0.941
Curative resection	4 (4.5)	4 (9.5)	0.272
CCRT	9 (10.2)	4 (9.5)	1.000

¹Values indicate statistical significance. mFOLFIRINOX: Modified FOLFIRINOX; sFOLFIRINOX: Standard FOLFIRINOX; ECOG-PS: Eastern Cooperative Oncology Group performance status; ULN: Upper limit of normal range; CA: Carbohydrate antigen; CCRT: Concurrent chemoradiotherapy.